Cell treatment on track for Phase II stroke trial

04/27/2012 | ProactiveInvestors.co.uk (U.K.)

The stem cell therapy ReN001 is being used in early clinical trials to treat 12 patients disabled by stroke, and an application is on track for a midstage study in 2013. The therapy is based on stem cell developer ReNeuron's lead neural stem cell line. ReNeuron is also developing treatments for peripheral arterial disease and retina diseases.

View Full Article in:

ProactiveInvestors.co.uk (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ